Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John Santini
AddedMar 31, 2024
UpdatedMay 31, 2026
John Santini

John Santini

Board Member, On Demand Therapeutics

CrunchbaseLinkedIn

John Santini's Career

On Demand Therapeutics
On Demand Therapeutics

Tyngsborough, MA, US

Board Member· Board
ApoGen Biotechnologies
ApoGen Biotechnologies

Seattle, WA, US

Co-Founder
Vergent Bioscience
Vergent Bioscience

Minneapolis, MN, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John Santini's Career

On Demand Therapeutics
On Demand Therapeutics
Series A$3.8M52008Tyngsborough, MA, US
Board Member· Board

Leadership at On Demand Therapeutics

David A. WeberDavid A. WeberBoard Member
Reza ZadnoReza ZadnoBoard Member

Similar to On Demand Therapeutics

OcuMedicOcuMedicMullica Hill, NJ, USMedical Devicesest. 2006OcuMedicMullica Hill, NJ, US · est. 2006

OcuMedic: Innovating therapeutic contact lenses for efficient drug delivery and medical use.

Series A · $250k7
Iscience SurgicalIscience SurgicalMenlo Park, CA, USMedical Devicesest. 1999Iscience SurgicalMenlo Park, CA, US · est. 1999

iScience Interventional designs and manufactures innovative biomedical devices for site-specific ocular therapies.

Series C · $22M30
ApoGen Biotechnologies
ApoGen Biotechnologies
Series A$11M72014Seattle, WA, US
Co-Founder

Leadership at ApoGen Biotechnologies

Keno GutierrezKeno GutierrezBoard Member
Daniel HarkiDaniel HarkiCo-Founder
Reuben HarrisReuben HarrisCo-Founder
Le Q ThongLe Q ThongCEO
Vergent Bioscience
Vergent Bioscience
Series B$34.4M132016Minneapolis, MN, US
CEO· C-Suite · Management

Leadership at Vergent Bioscience

Dean BanksDean BanksBoard Member
Doug KohrsDoug KohrsBoard Member
Dean B.Dean B.Board Member
Jeff JulkowskiJeff JulkowskiCo-Founder

Similar to Vergent Bioscience

CytoVerisCytoVerisFarmington, CT, USImaging Solutionsest. 2018CytoVerisFarmington, CT, US · est. 2018

AI-driven imaging solutions by CytoVeris, enhancing cancer detection and patient outcomes.

Series B · $8M23
Blaze BioscienceBlaze BioscienceSeattle, WA, USImaging, Tumor Paintest. 2010Blaze BioscienceSeattle, WA, US · est. 2010

Seattle-based Blaze Bioscience develops tumor paint technology for precise, real-time cancer cell visualization.

Series B · $55.4M38
On Target LaboratoriesOn Target LaboratoriesNorthbrook, IL, USCancer Detectionest. 2010On Target LaboratoriesNorthbrook, IL, US · est. 2010

On Target Laboratories innovates in developing and commercializing cell-targeting molecules for various cancers.

Series C · $111.7M75
Surge TherapeuticsSurge TherapeuticsCambridge, MA, USCancer Treatmentest. 2016Surge TherapeuticsCambridge, MA, US · est. 2016

SURGE: Innovating cancer treatment through targeted, timely immunotherapy for improved survival.

Series B · $58M7

John Santini's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to John Santini

Alice ZhangAlice ZhangFounder & CEO · Verge GenomicsMichael HarringtonMichael HarringtonFounder & CEO · Genoverde BiosciencesJeff YureckoJeff YureckoCo-Founder · StratifundNeil LittmanNeil LittmanFounder · BiovergeDrew SpaventaDrew SpaventaCo-Founder · Axon Ventures